Literature DB >> 24623334

Breast conservation therapy after neoadjuvant chemotherapy: optimization of a multimodality approach.

Abigail S Caudle1, Henry M Kuerer.   

Abstract

Neoadjuvant chemotherapy (NAC) is routinely used in locally advanced breast cancer, but is increasingly used in early stage patients. Even patients with advanced disease can achieve excellent outcomes with breast conservation therapy (BCT) after NAC. The use of NAC followed by BCT is an example of how multimodality therapy can optimize outcomes while limiting morbidity and preserving cosmetic outcomes. Open communication between the multidisciplinary team is crucial to selecting appropriate candidates for this approach.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  Breast cancer; breast conservation therapy; neoadjuvant chemotherapy

Mesh:

Year:  2014        PMID: 24623334     DOI: 10.1002/jso.23595

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

1.  Breast-conserving surgery in locally advanced breast cancer submitted to neoadjuvant chemotherapy. Safety and effectiveness based on ipsilateral breast tumor recurrence and long-term follow-up.

Authors:  Guilherme Freire Angotti Carrara; Cristovam Scapulatempo-Neto; Lucas Faria Abrahão-Machado; Maria Mitzi Brentani; João Soares Nunes; Maria Aparecida Azevedo Koike Folgueira; René Aloisio da Costa Vieira
Journal:  Clinics (Sao Paulo)       Date:  2017-03       Impact factor: 2.365

2.  Assessment of skin response in T4b breast carcinoma patients post-neoadjuvant chemotherapy.

Authors:  Abhishek Sharma; Shagun Mahajan; Sanjit Kumar Agrawal; Rosina Ahmed; Debdeep Dey
Journal:  Ecancermedicalscience       Date:  2021-07-28

3.  A single-center, randomized, parallel controlled study comparing the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer.

Authors:  Yijun Zhou; Tao Ouyang; Yuntao Xie; Tianfeng Wang; Zhaoqing Fan; Yingjian He; Aiping Lu; Yiqiang Liu; Jinfeng Li
Journal:  Breast Cancer Res Treat       Date:  2016-06-01       Impact factor: 4.872

4.  Neoadjuvant systemic therapy does not compromise local control after breast-conserving surgery: a single-center, propensity score matching study in China.

Authors:  Fan Yang; Si-Yu Wu; Miao Mo; Qin Xiao; Xia Yang; Ying-Ying Liu; Jian-Wei Li; Zhi-Ming Shao; Guang-Yu Liu
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.